CrossRoads Extremity Systems gained FDA clearance and launched the HiMax® Plus Widebody Fixation System, reportedly the only foot bone fusion system that provides flush insertion and a wide bridge for enhanced stability. The features and its compressive quality provide improved implant performance with more efficiency in the O.R. vs. alternative technologies.
HiMax Plus is the latest addition to the company’s Comprehensive Nitinol System, comprising five platforms of over 25 total implant options.
Chad Hollis, Vice President of Research and Development and Co-Founder, said, “HiMax Plus shows our continued commitment to be the leader in the development of nitinol applications for the lower extremities. The HiMax family is born from years of fine tuning and we believe the addition of HiMax Plus gives surgeons an enhanced nitinol implant that will be an optimal solution for all types of fusions.”
CrossRoads Extremity Systems gained FDA clearance and launched the HiMax® Plus Widebody Fixation System, reportedly the only foot bone fusion system that provides flush insertion and a wide bridge for enhanced stability. The features and its compressive quality provide improved implant performance with more efficiency in the O.R. vs....
CrossRoads Extremity Systems gained FDA clearance and launched the HiMax® Plus Widebody Fixation System, reportedly the only foot bone fusion system that provides flush insertion and a wide bridge for enhanced stability. The features and its compressive quality provide improved implant performance with more efficiency in the O.R. vs. alternative technologies.
HiMax Plus is the latest addition to the company’s Comprehensive Nitinol System, comprising five platforms of over 25 total implant options.
Chad Hollis, Vice President of Research and Development and Co-Founder, said, “HiMax Plus shows our continued commitment to be the leader in the development of nitinol applications for the lower extremities. The HiMax family is born from years of fine tuning and we believe the addition of HiMax Plus gives surgeons an enhanced nitinol implant that will be an optimal solution for all types of fusions.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.